ClinicalTrials.gg
RecruitingNCT03308474MYRIAMUpdated Jul 13, 2026

Myeloma Registry Platform (MYRIAM)

An observational study in Multiple Myeloma, sponsored by iOMEDICO AG. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by iOMEDICO AG · Observational

From the registry’s dates

  • Started Sep 2017; still recruiting 9 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 297 studies in Multiple Myeloma with a site in Germany — 49 open to participants now, 102 under way, 47 of them phase 3. Multiple Myeloma · Germany.

Planned enrollment
4th of 32
2,200 · median 298
Started
2017
with 15 others
Observational
32 of 297
9 open now
Primary completion
2026-12
later than 36 of 101 live
Registered
164th of 297
by date
Lead sponsor
8 of 297
iOMEDICO AG

Among the 297 studies in Multiple Myeloma with a site in Germany, this one is the 4th largest by planned enrollment of the 32 observational ones that give a count, is one of 16 that started in 2017, is one of 32 observational ones, reaches primary completion later than 36 of the 101 other live ones, and was the 164th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

49 of the 297 studies in Multiple Myeloma with a site in Germany are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 297 studies in Multiple Myeloma with a site in Germany, or all of them as a file.
02

Study summary

The purpose of the project is to set up a national, prospective, longitudinal, multicenter cohort study with associated satellites, a tumor registry platform, to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect patient-reported outcomes and to establish a decentralized biobank for patients with Multiple Myeloma in Germany.

Read the detailed description

MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study (tumor registry platform) with the purpose to record information on the antineoplastic treatment of multiple myeloma in Germany. The registry will follow patients for up to five years. It will identify common therapeutic sequences and changes in the treatment of the disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics and previous treatments are collected. During the course of observation data on all systemic treatments, radiotherapies, surgeries, and outcome are documented.

Health-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated for up to five years.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with multiple myeloma (MM) requiring systemic treatment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MM requiring systemic (first-, second- or ) treatment (closed for first-line / second-line recruitment)
  • Age ≥ 18 years
  • Written

    • Patients participating in the PRO satellite: signing of informed consent and completion of baseline questionnaire before, but not more than eight weeks before the start of respective systemic treatment
    • Patients not participating in the PRO satellite: signing of informed consent not later than four weeks after start of respective treatment, and not more than eight weeks before the start of respective systemic treatment
  • Sufficient German language skills for participation in the PRO satellite

Exclusion criteria

Exclusion Criteria:

  • No systemic therapy for myeloma
  • Patients already enrolled in studies that prohibit any participation in other studies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,200 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Interventions

  • OtherRoutine care as per site standard.

    Physician's choice according to patient's needs.

06

What researchers measure

Primary outcomes

  1. Course of treatment (treatment reality)

    Documentation of anamnestic data and therapy sequences

    Time frame: 5 years per patient

Secondary outcomes

  1. Best Response

    Documentation of response rates per line of treatment.

    Time frame: 5 years per patient

  2. Progression-free survival

    Documentation of progression-free survival per line of treatment.

    Time frame: 5 years per patient

  3. Overall survival

    Documentation of overall survival time.

    Time frame: 5 years per patient

  4. Health-related quality of life (Patient-reported outcome)

    EORTC QLQ-C30 core questionnaire.

    Time frame: 5 years per patient

  5. Myeloma-specific health-related quality of life (Patient-reported outcome)

    EORTC QLQ-MY20, the myeloma specific module.

    Time frame: 5 years per patient

  6. Quality of life (Patient-reported outcome)

    Brief Pain Inventory (BPI)

    Time frame: 5 years per patient

07

Study locations

1 of 1 sites recruiting
  • Multiple sites all over germany
    Multiple Sites, Germany
    Recruiting
08

References and documents

Publications

  • Engelhardt M, Ihorst G, Singh M, Rieth A, Saba G, Pellan M, Lebioda A. Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany. Clin Lymphoma Myeloma Leuk. 2021 Feb;21(2):e160-e175. doi: 10.1016/j.clml.2020.10.002. Epub 2020 Oct 24. PubMed 33218965 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2017 (actual). Primary completion is estimated for Dec 2026, 111 months after the start.

Of 66 industry-sponsored observational studies under Multiple Myeloma, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 70. This study's planned 111 months is above that.

Counting every sponsor, half of 239 studies reached it within 61 months; a quarter within 30 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2017
First posted
Oct 12, 2017
StartActual
Sep 25, 2017
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03308474
Lead sponsor
iOMEDICO AG
Collaborators
Deutsche Studiengruppe Multiples Myelom (DSMM)
Responsible party
Sponsor
First posted
Oct 12, 2017
Start date
Sep 25, 2017
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jul 13, 2026

Study contacts

Martina Jänicke, PhD
Contact
info@iomedico.de
+49 761 15242-0
Hermann Einsele, Prof MD
study chair · Wuerzburg University Hospital
Monika Engelhardt, Prof MD
study chair · Universitätsklinikum Freiburg
Tobias Dechow, Prof MD
study chair · Onkologie Ravensburg
Wolfgang Knauf, Prof MD
study chair · Centrum für Hämatologie und Onkologie Bethanien
Norbert Marschner, MD
study chair · Praxis für interdisziplinäre Onkologie & Hämatologie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion